The binding capacity in the AML model for both untreated and relapse states was markedly higher than in the ALL model, and there was a statistically significant increase in the AML model between E-selectin binding of untreated and relapse disease that was not seen in the ALL model. This evidence concerns the gene SELE and acute myeloid leukemia.